Tang Guodong, Wu Jun, Xiao Gelei, Huo Lei
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan 410078, P.R. China.
Mol Med Rep. 2015 Apr;11(4):2838-44. doi: 10.3892/mmr.2014.3101. Epub 2014 Dec 16.
Glioma is the most common malignant and fatal primary tumor in the central nervous system in adults. Recent data has suggested a profound role for microRNAs (miRs) in cancer progression. The present study demonstrated, via quantitative polymerase chain reaction (qPCR) analysis, that miR-203 expression was markedly lower in highly invasive U87MG glioma cells and glioma tissues. Wound healing and Transwell assays demonstrated that restoration of miR-203 expression inhibited U87MG cell migration and invasion. Restoration of miR-203 expression additionally sensitized the cells to temozolomide (TMZ) as determined by MTS assay. By contrast, miR-203 inhibition in A172 cells exerted opposite effects. Bioinformatic analysis combined with experimental analysis revealed that miR-203 directly targeted E2F3 via the conserved miR-203 target site within the E2F3 3'-untranslational region. E2F3 knockdown with specific small hairpin RNA also inhibited U87MG cell migration and invasion, and sensitized them to TMZ. Importantly, miR-203 and E2F3 showed inverse expression patterns in invasive glioma tissues, as demonstrated by qPCR and luciferase assay. These results suggested that miR-203 may function as a tumor suppressor in glioma progression and that the miR-203/E2F3 axis may be a novel candidate in the development of rational therapeutic strategies for glioma.
胶质瘤是成人中枢神经系统中最常见的恶性致命原发性肿瘤。最近的数据表明,微小RNA(miR)在癌症进展中发挥着重要作用。本研究通过定量聚合酶链反应(qPCR)分析表明,miR-203在高侵袭性U87MG胶质瘤细胞和胶质瘤组织中的表达明显较低。伤口愈合和Transwell试验表明,miR-203表达的恢复抑制了U87MG细胞的迁移和侵袭。如MTS试验所测定,miR-203表达的恢复还使细胞对替莫唑胺(TMZ)敏感。相比之下,在A172细胞中抑制miR-203则产生相反的效果。生物信息学分析与实验分析相结合表明,miR-203通过E2F3 3'-非翻译区内保守的miR-203靶位点直接靶向E2F3。用特异性小发夹RNA敲低E2F3也抑制了U87MG细胞的迁移和侵袭,并使它们对TMZ敏感。重要的是,qPCR和荧光素酶试验表明,miR-203和E2F3在侵袭性胶质瘤组织中呈现相反的表达模式。这些结果表明,miR-203可能在胶质瘤进展中起肿瘤抑制作用,并且miR-203/E2F3轴可能是开发合理的胶质瘤治疗策略的新候选者。